retatrutide type 2 diabetes phase 2 results 2024 2025 There are many great research studies to read on this topic! Below are a few to check out- Harris, L. H., Jastreboff, A. M., Aronne, L. J., et al. (2023). Retatrutide, a Retatrutide, a TRIPLE agonist (GLP1,

45.3% achieved 30% weight loss

We found no interactions, except between prior suicide attempts and sex in the comparison of GLP-1 RAs and SGLT-2 inhibitors, indicating that the effect of prior suicide attempts on the risk of a subsequent suicide attempt is greater among men

As an example of a combined GLP-1 + FIM intervention, eligible patients could receive both GLP-1 therapy and a FIM intervention emphasizing foods to support weight maintenance, reduce side effects, minimize loss of muscle and bone mass, and promote nutrient adequacy

This sets up a regulatory fragmentation nightmare

Barber TM, Kabisch S, Pfeiffer AFH, Weickert MO